Entera Bio reports H1 net loss $4.5M, cash $9.1M; updates on EB613 and EB612 trials

Entera Bio Ltd.

2023-Q2 EPS reported $0.16

H1 2023 net loss $4.5M ($0.16/share) vs $7.0M ($0.24) in H1 2022.
Cash and equivalents $9.1M expected to fund operations into Q3 2024.
R&D expenses $2.1M (down 32% YoY); G&A $2.4M (down 41% YoY).
EB613 Phase 3 initiation depends on FDA review of FNIH-ASBMR SABRE BQP qualification.
Phase 1B study of next-gen EB612 platform (45 subjects, 3 cohorts) started May 2023; H2 2023 data readout expected.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Entera Bio Ltd. reported the six months ended June 30, 2023 results: net income Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023, EPS $0.16 per ordinary share (basic and diluted).

Period: the six months ended June 30, 2023
Net income: Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023
EPS: $0.16 per ordinary share (basic and diluted)
Result: reported results

Exact text from the filing

Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023, as compared to $7.0 million, or $0.24 per ordinary share (basic and diluted), for the six months ended June 30, 2022.

View on SEC.gov

Browse all earnings releases →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-002832

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.